Cohance Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cohance Lifesciences (formerly Suven Pharmaceuticals) has informed the exchanges that its Board of Directors will meet on Thursday, February 12, 2026, to consider and approve the unaudited financial results (standalone and consolidated) for the quarter and nine months ending December 31, 2025. In line with SEBI insider trading rules, the trading window for company insiders has been closed from January 1, 2026, to February 14, 2026 (both days inclusive). The filing was made under Regulation 29 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. This is a routine compliance intimation with no new business or financial details disclosed at this stage.
No direct impact on shareholders, but it confirms Q3 FY26 earnings will be announced around mid-February 2026, which is the next potential stock-moving catalyst. The trading window closure restricts insider buying or selling until after results are declared.